Plasmacytoid Dendritic Cells and Interferon-alpha in Aicardi-Goutières Syndrome

Abstract

In Aicardi-Goutières syndrome (AGS), as in systemic lupus erythematosus (SLE) and Sjögren's syndrome, an increased level of interferon alpha (IFN-α) is involved in the pathogenesis of the disease. In SLE and Sjögren's syndrome, cytokine production originates in plasmacytoid dendritic cells (pDCs) under the influence of immune complexes formed by DNA and RNA from improperly removed apoptotic or necrotic cells, together with IgG autoantibodies. We studied the role of soluble factors in the serum or cerebrospinal fluid (CSF) of AGS patients and their capacity to stimulate pDCs to produce IFN-α. Our findings show that, in contrast to SLE, there is no decrease in the number of circulating pDCs in AGS patients. Secondly, unlike the autoantibodies in the serum of patients with SLE or Sjögren's syndrome, there is no increased frequency of antinuclear antibodies (ANA) or other soluble factors inducing IFN-α from pDCs. These data indicate that the origin of IFN-α in AGS is different from that in the autoimmune diseases tested.

Key words

Aicardi-Goutières syndrome - systemic lupus erythematosus - interferon-alpha - antinuclear antibodies

References

• 1 Aicardi J, Goutières F. Systemic lupus erythematosus or Aicardi-Goutières syndrome?.  Neuropediatrics. 2000;  31 113
• 2 Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H. et al . Transgenic expression of IFN-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration.  J Immunol. 1998;  161 5016-5026
• 3 Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney J. et al . Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.  Arthritis Rheum. 2004;  50 3580-3590
• 4 Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S. et al . Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus.  J Exp Med. 2005;  202 1131-1139
• 5 Båve U, Alm GV, Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer.  J Immunol. 2000;  165 3519-3526
• 6 Båve U, Vallin H, Alm GV, Rönnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines.  J Autoimmun. 2001;  17 71-80
• 7 Båve U, Nordmark G, Lövgren T Rönnelid J, Cajander S, Eloranta ML. et al . Activation of the type I interferon system in primary Sjögren'drome.  Arthritis Rheum. 2005;  52 1185-1195
• 8 Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin . et al . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies.  Lupus. 2000;  9 664-671
• 9 Borg FAY, Isenberg DA. Syndromes and complications of interferon therapy.  Curr Opin Rheumatol. 2007;  19 61-66
• 10 Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.  J Autoimmun. 2003;  20 15-25
• 11 Çaksen H, Odabas D, Bülent A. Seizures in a boy with subacute sclerosing panencephalitis during high-dose intrathecal interferon-alpha therapy.  Pediatr Neurol. 2002;  27 75
• 12 Çaksen H, Odabas D, Ömer A, Bülent A, Oguz T. Onset of generalized seizures after intrathecal interferon therapy of SSPE.  Pediatr Neurol. 2003;  29 78-79
• 13 Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T. et al . Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α.  Brain Res. 1999;  835 46-61
• 14 Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells.  J Autoimmun. 1998;  11 465-470
• 15 Crow YJ, Leitch A, Hayward BE, Garner A, Parmer R, Griffith E. et al . Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection.  Nat Genet. 2006;  38 910-916
• 16 Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M. et al . Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus.  Nat Genet. 2006;  38 917-920
• 17 Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and congenital infection-like syndrome.  Neuropediatrics. 2000;  31 155-158
• 18 Laet C De, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutières syndrome.  Neuropediatrics. 2005;  36 399-402
• 19 Ehrenstein MR, MacSweeney E, Swane M, Worman CP, Goldstone AH, Isenberg DA. Apperarance of anti-DNA antibodies in patients treated with interferon-α.  Arthritis Rheum. 1993;  36 79-280
• 20 Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K. et al . Clearance deficiency and systemic lupus erythematosus (SLE).  J Autoimmun. 2007;  , ahead of publication
• 21 Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C. Pathophysiology of Sjögren's syndrome.  Arch Med Res. 2006;  37 921-932
• 22 Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoim-mune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.  World J Gastroenterol. 2006;  12 5787-5792
• 23 Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE. et al . Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.  Cell Immunol. 2002;  218 74-86
• 24 Goutières F. Aicardi-Goutières syndrome.  Brain Dev. 2005;  27 201-206
• 25 Hilario MOE, Len CA, Roja SC, Terreri MT, Almeida G, Andrade LEC. Frequency of antinuclear antibodies in children and adolescents.  Clin Pediatr. 2004;  43 637-642
• 26 Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.  Arthritis Rheum. 2000;  43 1431-1442
• 27 Ito T, Kanzler H, Duramad O, Cao W, Liu YJ. Specialization, kinetics, and repertoire of type I interferon responses by human plasmacytoid predendritic cells.  Blood. 2006;  107 2423-2431
• 28 Lanzi G, Fazzi E, D’Arrigo S. Aicardi-Goutières syndrome: a description of 21 new cases and a comparison with the literature.  Eur J Paediatr Neurol. 2002;  6A A9-A22
• 29 Lebon P, Meritet JF, Krivine A, Rozenberg F. Interferon and Aicardi-Goutières syndrome.  Eur J Paediatr Neurol. 2002;  6 A47-A53
• 30 Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA. et al . Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus.  Nat Genet. 2007;  39 1065-1067
• 31 Lenert PS. Targeting toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.  Arthritis Res Ther. 2006;  8 203
• 32 Morita M, Stamp G, Robins P, Dulic A, Rosewel I, Hrivnak G. et al . Gene-targeted mice lacking the Trex1 (DNase III) 3′-5′ DNA exonuclease develop inflammatory myocarditis.  Mol Cell Biol. 2004;  24 6719-6727
• 33 Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutières syndrome - report of two sisters.  Neuropediatrics. 2005;  36 40-44
• 34 Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K. et al . Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome.  Am J Hum Genet. 2007;  80 811-815
• 35 Rice G, Patrick T, Parmar R, Taylor C, Aeby A, Aicardi J. et al . Clinical and molecular phenotype of Aicardi-Goutieres syndrome.  Am J Hum Genet. 2007;  81 713-715
• 36 Robak E, Sysa-Jedrzejowska A, Robak T, Smolewski P. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms.  Clin Rheumatol. 2004;  25 225-233
• 37 Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumor.  J Intern Med. 1990;  227 207-210
• 38 Rönnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system.  Arthritis Res Ther. 2003;  5 68-75
• 39 Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart T, Kono DH. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice.  J Exp Med. 2003;  197 777-788
• 40 Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus.  Drugs. 2006;  66 1933-1948
• 41 Sato Y, Miyata M, Nishimaki T, Kochi H, Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro.  J Rhematol. 1999;  26 294-301
• 42 Shakil AO, Bisceglie AM Di, Hoofnagle JH. Seizures during alpha interferon therapy.  J Hepatol. 1996;  24 48-51
• 43 Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S. et al . The nature of the principal type 1 interferon-producing cells in human blood.  Science. 1999;  284 1835-1837
• 44 Vallin H, Blomberg S, Alm G, Cederblad B, Rönnblom L. Patients with systemic lupus erythromatosus have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells.  Clin Exp Immunol. 1999;  115 196-202
• 45 Vallin H, Perers A, Alm G, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus.  J Immunol. 1999;  162 6306-6313
• 46 Wanankukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O. ANA in healthy children.  J Allergy Immunol. 2005;  23 153-157
• 47 Wandstrat AE, Carr-Johnson F, Branch V, Gray H, Fairhurst AM, Reimold A. et al . Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus.  J Autoimmun. 2006;  27 153-160
• 48 Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.  Semin Arthritis Rheum. 2002;  32 163-173

Correspondence